293 related articles for article (PubMed ID: 7505875)
1. Immunogenicity of Vibrio cholerae O1 fimbriae in animal and human cholera.
Ehara M; Ichinose Y; Iwami M; Utsunomiya A; Shimodori S; Kangethe SK; Neves BC; Supawat K; Nakamura S
Microbiol Immunol; 1993; 37(9):679-88. PubMed ID: 7505875
[TBL] [Abstract][Full Text] [Related]
2. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
Kundu J; Mazumder R; Srivastava R; Srivastava BS
FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
[TBL] [Abstract][Full Text] [Related]
3. Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.
Kamruzzaman M; Kelly M; Charles RC; Harris JB; Calderwood SB; Akter A; Biswas R; Kaisar MH; Bhuiyan TR; Ivers LC; Ternier R; Jerome JG; Pfister HB; Lu X; Soliman SE; Ruttens B; Saksena R; Mečárová J; Čížová A; Qadri F; Bystrický S; Kováč P; Xu P; Ryan ET
mSphere; 2021 Aug; 6(4):e0011421. PubMed ID: 34232076
[TBL] [Abstract][Full Text] [Related]
4. Induction of fimbriated Vibrio cholerae O139.
Ehara M; Iwami M; Ichinose Y; Hirayama T; Albert MJ; Sack RB; Shimodori S
Clin Diagn Lab Immunol; 1998 Jan; 5(1):65-9. PubMed ID: 9455882
[TBL] [Abstract][Full Text] [Related]
5. Protection against Vibrio cholerae El Tor infection by specific antibodies against mannose-binding hemagglutinin pili.
Osek J; Svennerholm AM; Holmgren J
Infect Immun; 1992 Nov; 60(11):4961-4. PubMed ID: 1356934
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and protective capacity of inactivated "vibrio cholerae" whole cell vaccines.
Cryz SJ; Fürer E; Germanier R
Dev Biol Stand; 1983; 53():67-72. PubMed ID: 6873478
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and protective role of three formulations of oral cholera vaccine.
Kalambaheti T; Chaisri U; Srimanote P; Pongponratn E; Chaicumpa W
Vaccine; 1998; 16(2-3):201-7. PubMed ID: 9607031
[TBL] [Abstract][Full Text] [Related]
8. Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio cholerae O1 El Tor challenge in mice.
Rollenhagen JE; Kalsy A; Cerda F; John M; Harris JB; Larocque RC; Qadri F; Calderwood SB; Taylor RK; Ryan ET
Infect Immun; 2006 Oct; 74(10):5834-9. PubMed ID: 16988262
[TBL] [Abstract][Full Text] [Related]
9. Role of antibodies against biotype-specific Vibrio cholerae pili in protection against experimental classical and El Tor cholera.
Osek J; Jonson G; Svennerholm AM; Holmgren J
Infect Immun; 1994 Jul; 62(7):2901-7. PubMed ID: 7911787
[TBL] [Abstract][Full Text] [Related]
10. Antibodies directed against the toxin-coregulated pilus isolated from Vibrio cholerae provide protection in the infant mouse experimental cholera model.
Sun DX; Mekalanos JJ; Taylor RK
J Infect Dis; 1990 Jun; 161(6):1231-6. PubMed ID: 1971653
[TBL] [Abstract][Full Text] [Related]
11. Purification and characterization of vibrio cholerae O139 fimbriae.
Yamashiro T; Nakasone N; Honma Y; Albert MJ; Iwanaga M
FEMS Microbiol Lett; 1994 Jan; 115(2-3):247-52. PubMed ID: 7908003
[TBL] [Abstract][Full Text] [Related]
12. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
Mayo-Smith LM; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Calderwood SB; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847368
[TBL] [Abstract][Full Text] [Related]
13. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
Liao J; Gibson JA; Pickering BS; Watnick PI
mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
[TBL] [Abstract][Full Text] [Related]
14. Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility.
Bishop AL; Schild S; Patimalla B; Klein B; Camilli A
Infect Immun; 2010 Oct; 78(10):4402-20. PubMed ID: 20679439
[TBL] [Abstract][Full Text] [Related]
15. Cumulative protective efficacy of rZot and rAce combination in challenge experiments with wild type Vibrio cholerae in mouse model.
Anvari S; Najar-Peerayeh S; Behmanesh M; Bakhshi B
Hum Vaccin Immunother; 2018; 14(9):2323-2328. PubMed ID: 29852089
[TBL] [Abstract][Full Text] [Related]
16. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
[TBL] [Abstract][Full Text] [Related]
17. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
[TBL] [Abstract][Full Text] [Related]
18. Experimental studies on cholera immunization. 4. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity.
Svennerholm AM
Int Arch Allergy Appl Immunol; 1975; 49(4):434-52. PubMed ID: 808500
[TBL] [Abstract][Full Text] [Related]
19. Infection and immunity to Vibrio cholerae, Salmonella typhimurium and Escherichia coli in a rabbit model.
Guinée PA; Jansen WH; Rijpkema SG
Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Nov; 270(1-2):260-9. PubMed ID: 2464884
[TBL] [Abstract][Full Text] [Related]
20. A review of the current status of enteric vaccines.
Levine MM; Noriega F
P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
